RxDoctor Payments Data

Ryan Hurt, MD

Internal Medicine · Rochester, MNNPI 1578603163

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (58.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Every reported general payment came from a single manufacturer, Nestle Healthcare Nutrition Inc.. 2023 is the largest year on record at $6,540, 2.2 times the $3,000 reported in 2020. Among internal medicine clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,877in general payments, 2019–2025

Across 39 payments — averaging $484.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nestle Healthcare Nutrition Inc.$19K
$168,094in research payments, 2019–2025

Across 17 payments — averaging $9887.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Zealand Pharma A/s$148K
  • Pfizer$20K

What the payments were for

  • Consulting fees$10,94258%
  • Speaking & faculty fees$3,75020%
  • Travel & lodging$2,30712%
  • Food & beverage$1,87810%

General payments by program year

20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Nestle Healthcare Nutrition Inc.39$18,877

How this compares

$18,877 in reported general payments places this provider in the 95th percentile of 1,924 internal medicine providers in Minnesota.

See all internal medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$14,031
Medicare patients
55
Services billed
126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Guanfacine Hcl15$508
Rosuvastatin Calcium14$156
Amlodipine Besylate11$147

Paid to pharmacies, not to this prescriber.

Other internal medicine in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →